BEYOND AIR INC (XAIR) Stock Overview
USA - NASDAQ:XAIR - US08862L2025 - Common Stock
XAIR Key Statistics, Chart & Performance
The current stock price of XAIR is 2.14 USD. In the past month the price decreased by -13.01%. In the past year, price decreased by -73.38%.
XAIR Latest News, Press Relases and Analysis
XAIR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.42 | 220.78B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.47 | 195.91B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.27 | 149.82B | ||
| SYK | STRYKER CORP | 29.71 | 145.96B | ||
| MDT | MEDTRONIC PLC | 16.94 | 120.15B | ||
| BDX | BECTON DICKINSON AND CO | 13.02 | 53.26B | ||
| IDXX | IDEXX LABORATORIES INC | 53.36 | 51.27B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.61 | 44.68B | ||
| RMD | RESMED INC | 27.17 | 37.87B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.77 | 35.68B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.26 | 27.76B | ||
| DXCM | DEXCOM INC | 41.37 | 27.58B |
Related stock screener links
About XAIR
Company Profile
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company is headquartered in Garden City, New York and currently employs 61 full-time employees. The company went IPO on 2019-05-07. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. The company has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The firm is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Company Info
BEYOND AIR INC
900 Stewart Ave, Suite 301
Garden City NEW YORK 11530 US
CEO: Steven Lisi
Employees: 107
Phone: 15166658200
BEYOND AIR INC / XAIR FAQ
What does XAIR do?
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company is headquartered in Garden City, New York and currently employs 61 full-time employees. The company went IPO on 2019-05-07. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. The company has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The firm is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
What is the current price of XAIR stock?
The current stock price of XAIR is 2.14 USD. The price increased by 2.88% in the last trading session.
Does BEYOND AIR INC pay dividends?
XAIR does not pay a dividend.
What is the ChartMill rating of BEYOND AIR INC stock?
XAIR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of BEYOND AIR INC (XAIR)?
BEYOND AIR INC (XAIR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.93).
Is BEYOND AIR INC (XAIR) expected to grow?
The Revenue of BEYOND AIR INC (XAIR) is expected to grow by 234.98% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of XAIR stock?
BEYOND AIR INC (XAIR) has a market capitalization of 11.49M USD. This makes XAIR a Nano Cap stock.
XAIR Technical Analysis
XAIR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XAIR. Both the profitability and financial health of XAIR have multiple concerns.
XAIR Financial Highlights
Over the last trailing twelve months XAIR reported a non-GAAP Earnings per Share(EPS) of -11.93. The EPS decreased by -76.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -149.8% | ||
| ROE | -424.25% | ||
| Debt/Equity | 0.97 |
XAIR Forecast & Estimates
11 analysts have analysed XAIR and the average price target is 11.42 USD. This implies a price increase of 433.83% is expected in the next year compared to the current price of 2.14.
For the next year, analysts expect an EPS growth of 77.15% and a revenue growth 234.98% for XAIR